[1] LI Y, MCKELVIE J, MCLINTOCK C. Visual Outcomes of Patients With Peripheral Ulcerative Keratitis and the Effect of Immunosuppression-A 6-Year Experience in Queensland, Australia. Eye Contact Lens. 2022;48(7):283-288.
[2] FU L, JONES S. Peripheral Ulcerative Keratitis. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024.
[3] SHARMA N, SINHA G, SHEKHAR H, et al. Demographic profile, clinical features and outcome of peripheral ulcerative keratitis: a prospective study. Br J Ophthalmol. 2015;99(11):1503-1508.
[4] CóRDOBA A, MEJíA LF, GONZáLEZ N, et al. Unusual Corneal Sarcoidosis Manifestations. Ocul Immunol Inflamm. 2023;31(5):940-944.
[5] ARTIFONI M, ROTHSCHILD PR, BRÉZIN A, et al. Ocular inflammatory diseases associated with rheumatoid arthritis. Nat Rev Rheumatol. 2014;10(2):108-116.
[6] WATANABE R, ISHII T, YOSHIDA M, et al. Ulcerative keratitis in patients with rheumatoid arthritis in the modern biologic era: a series of eight cases and literature review. Int J Rheum Dis. 2017;20(2):225-230.
[7] TAVASSOLI S, WONG N, CHAN E. Ocular manifestations of rosacea: A clinical review. Clin Exp Ophthalmol. 2021;49(2):104-117.
[8] XIA A, DIETRICH-NTOUKAS T, PLEYER U. Effect of Anti-TNF Treatment on Mooren’s Ulcer: A Case Series and Review of the Literature. Ocul Immunol Inflamm. 2023; 31(4):675-681.
[9] LAHOTI S, WEISS M, JOHNSON DA, et al. Superior limbic keratoconjunctivitis: a comprehensive review. Surv Ophthalmol. 2022;67(2):331-341.
[10] BAQUET-WALSCHEID K, NEß T, MAIER PC, et al. Peripheral Ulcerative Keratitis: Clinical Characteristics, Differential Diagnoses and Therapeutic Concepts. Klin Monbl Augenheilkd. 2024;241(5):633-643.
[11] SCHAAP OL, FELTKAMP TE, BREEBAART AC. Circulating antibodies to corneal tissue in a patient suffering from Mooren’s ulcer (ulcus rodens corneae). Clin Exp Immunol. 1969;5(4):365-370.
[12] ALLANSMITH MR, MCCLELLAN BH. Immunoglobulins in the human cornea. Am J Ophthalmol. 1975;80(1):123-132.
[13] MONDINO BJ, BRADY KJ. Distribution of hemolytic complement in the normal cornea. Arch Ophthalmol. 1981;99(8):1430-1433.
[14] MüLLER LJ, PELS E, SCHURMANS LR, et al. A new three-dimensional model of the organization of proteoglycans and collagen fibrils in the human corneal stroma. Exp Eye Res. 2004;78(3):493-501.
[15] MARSOVSZKY L, RESCH MD, NÉMETH J, et al. In vivo confocal microscopic evaluation of corneal Langerhans cell density, and distribution and evaluation of dry eye in rheumatoid arthritis. Innate Immun. 2013;19(4):348-354.
[16] DOMINGUEZ-CASAS LC, SáNCHEZ-BILBAO L, CALVO-RíO V, et al. Biologic therapy in severe and refractory peripheral ulcerative keratitis (PUK). Multicenter study of 34 patients. Semin Arthritis Rheum. 2020;50(4):608-615.
[17] 中华医学会眼科学分会角膜病学组.中国免疫相关性边缘性角膜病临床诊疗专家共识(2022年)[J].中华眼科杂志,2022,58(2):90-95.
[18] LUCCHINO L, MASTROGIUSEPPE E, GIOVANNETTI F, et al. Anterior Segment Optical Coherence Tomography for the Tailored Treatment of Mooren’s Ulcer: A Case Report. J Clin Med. 2024;13(18):5384.
[19] AVILÉS-PRIETO J, CARO-MAGDALENO M, RODRÍGUEZ-DE-LA-RÚA-FRANCH E. Peripheral Ulcerative Keratopathy following Systemic Treatment with Bortezomib: A Case Report. Ocul Immunol Inflamm. 2024;32(4):470-472.
[20] CHI H, HAO W, QI X, et al. A proteomic approach towards understanding the pathogenesis of Mooren’s ulcer. Exp Eye Res. 2021;205:108509.
[21] LEE DH, MARGOLIS MS, IOVIENO A, et al. Superior limbic keratoconjunctivitis: Update on pathophysiology and management. Ocul Surf. 2023;28:144-152.
[22] AHN H, JI YW, JUN I, et al. Effects of meibomian gland dysfunction and aqueous deficiency on friction-related disease. Ocul Surf. 2022;26:295-299.
[23] KARAMPATAKIS V, KONIDARIS V, MICHAILIDOU M, et al.Peripheral corneal ulceration associated with rheumatoid arthritis. The American journal of case reports. 2013;14:318-321.
[24] HASSANPOUR K, H ELSHEIKH R, ARABI A, et al. Peripheral Ulcerative Keratitis: A Review. Ophthalmic Vis Res. 2022;17(2):252-275.
[25] LEE GR. The Balance of Th17 versus Treg Cells in Autoimmunity. Int J Mol Sci. 2018;19(3):730.
[26] RAZA IGA, CLARKE AJ. B Cell Metabolism and Autophagy in Autoimmunity. Front Immunol. 2021;12:681105.
[27] HUANG Y, BA X, HAN L, et al. T peripheral helper cells in autoimmune diseases: What do we know? Front Immunol. 2023;14:1145573.
[28] ROUSTA ST. Pediatric blepharokeratoconjunctivitis: is there a ‘right’ treatment? Curr Opin Ophthalmol. 2017;28(5):449-453.
[29] ANITHA V, GHORPADE A, RAVINDRAN M. A modified Tenons sling annular graft for advanced peripheral ulcerative keratitis with an hourglass cornea. Indian J Ophthalmol. 2022;70(2):655-657.
[30] CHENG C, ZHU M, LIN T, et al. Recharacterization of superior limbic keratoconjunctivitis via a subdividing grading method in 236 Chinese patients. Graefes Arch Clin Exp Ophthalmol. 2022;260(7):2291-2298.
[31] LIM YW, LIEW OH. Perinuclear Antineutrophil Cytoplasmic Antibody-Associated Ocular Manifestations: Case Series and Literature Review. Ocul Immunol Inflamm. 2024:1-4.doi: 10.1080/09273948.2024.2346820.
[32] RUUTILA M, FAGERHOLM P, LAGALI N, et al. Diagnostic Criteria for Terrien Marginal Degeneration: Nordic Terrien Degeneration Study. Cornea. 2021;40(2): 133-141.
[33] MOUNIR A, ABDELLAH MM, AWNY I, et al. Demographic, clinical and tomographic characteristics of pellucid marginal degeneration patients in South Egyptian population. Int Ophthalmol. 2022;42(10):3237-3242.
[34] DING Y, MURRI MS, BIRDSONG OC, et al. Terrien marginal degeneration. Survey of Ophthalmology. 2019;64(2):162-174.
[35] ADEBAYO A, TAUBER J, TINGLEY J, et al. Assessing an Exposure Keratopathy Prevention Strategy in Mechanically Ventilated Patients: A Retrospective Study. Eye Contact Lens. 2024;50(2):70-72.
[36] OGRA S, SIMS JL, MCGHEE CNJ, et al. Ocular complications and mortality in peripheral ulcerative keratitis and necrotising scleritis: The role of systemic immunosuppression. Clin Exp Ophthalmol. 2020;48(4):434-441.
[37] CAO Y, ZHANG W, WU J, et al. Peripheral Ulcerative Keratitis Associated with Autoimmune Disease: Pathogenesis and Treatment. J Ophthalmol. 2017;2017:1-12.
[38] KISER KA, HONG AR, LUBNIEWSKI A, et al. Topical steroids to the superior bulbar conjunctiva for the treatment of superior limbic keratoconjunctivitis (SLK). Ocul Surf. 2022;23:114-115.
[39] RUIZ-LOZANO RE, RAMOS-DAVILA EM, GARZA-GARZA LA, et al. Rheumatoid arthritis-associated peripheral ulcerative keratitis outcomes after early immunosuppressive therapy. Br J Ophthalmol. 2023;107(9):1246-1252.
[40] BURSKA AN, HUNT L, BOISSINOT M, et al. Autoantibodies to posttranslational modifications in rheumatoid arthritis. Mediators Inflamm. 2014;2014:492873.
[41] CLEWES AR, DAWSON JK, KAYE S, et al. Peripheral ulcerative keratitis in rheumatoid arthritis: successful use of intravenous cyclophosphamide and comparison of clinical and serological characteristics. Ann Rheum Dis. 2005; 64(6):961-962.
[42] KARACA I, TRAN EM, PARK S, et al. Intravenous cyclophosphamide therapy for patients with severe ocular inflammatory diseases who failed other immunomodulatory therapies. J Ophthalmic Inflamm Infect. 2024;14(1):12.
[43] HATA M, NAKAMURA T, SOTOZONO C, et al. Atypical continuous keratitis in a case of rheumatoid arthritis accompanying severe scleritis. Cornea. 2012;31(12):1493.
[44] DOMINGUEZ-CASAS LC, SáNCHEZ-BILBAO L, CALVO-RíO V, et al. Biologic therapy in severe and refractory peripheral ulcerative keratitis (PUK). Multicenter study of 34 patients. Semin Arthritis Rheum. 2020;50(4):608-615.
[45] ILIOU C, ANTHIS N, TSIFETAKI N, et al. Clinical images: Corneal melt in a woman with longstanding rheumatoid arthritis. Arthritis Rheum. 2012;64(1):253.
[46] SHEPPARD M, LASKOU F, STAPLETON PP, et al. Tocilizumab (Actemra). Hum Vaccin Immunother. 2017;13(9):1972-1988.
[47] COHEN F, GABISON EE, STéPHAN S, et al. Peripheral ulcerative keratitis in rheumatoid arthritis patients taking tocilizumab: paradoxical manifestation or insufficient efficacy? Rheumatology (Oxford). 2021; 60(11):5413-5418.
[48] BENUCCI M, BERNARDINI P, COCCIA C, et al. JAK inhibitors and autoimmune rheumatic diseases. Autoimmun Rev. 2023;22(4):103276.
[49] SHAH RJ, BANERJEE S, RAYCHAUDHURI S, et al. JAK-STAT inhibitors in Immune mediated diseases: An Overview. Indian J Dermatol Venereol Leprol. 2023;89(5): 691-699.
[50] WEN J, HU H, CHEN M, et al. Role of Janus Kinase (JAK) Inhibitor in Autoimmune Ocular Inflammation: A Systematic Review. J Immunol Res. 2021;2021:2324400.
[51] CALVO-RÍO V, SÁNCHEZ-BILBAO L, ÁLVAREZ-REGUERA C, et al. Baricitinib in severe and refractory peripheral ulcerative keratitis: a case report and literature review. Ther Adv Musculoskelet Dis. 2022;14:1759720x221137126.
[52] LIU J, SHI W, LI S, et al. Modified lamellar keratoplasty and immunosuppressive therapy guided by in vivo confocal microscopy for perforated Mooren’s ulcer. Br J Ophthalmol. 2015;99(6):778-783.
[53] AZIZI S, SUBHI Y, RASMUSSEN MLR. Surgical Treatment of Corneal Shield Ulcer in Vernal Keratoconjunctivitis: A Systematic Review. J Pers Med. 2023;13(7):1092.
[54] BULUT O, MUSAYEVA G, SELVER OB. Impact of adjuvant amniotic membrane transplantation in infectious ulcerative keratitis. Int Ophthalmol. 2023;43(3): 915-923.
[55] SABHAPANDIT S, MURTHY SI, SHARMA N, et al. Surgical Management of Peripheral Ulcerative Keratitis: Update on Surgical Techniques and Their Outcome. Clinical Ophthalmology. 2022;16:3547-3557.
[56] KUSUMESH R, AMBASTHA A, SINGH A, et al. Clinical outcome and course of Tenon’s patch graft in corneal perforation and descemetocele. Indian J Ophthalmol. 2022;70(12):4257-4262.
[57] JHANJI V, YOUNG AL, MEHTA JS, et al. Management of corneal perforation. Surv Ophthalmol. 2011;56(6):522-538.
[58] HEATHER M. SKEENS MAEJH, MD. Large-diameter penetrating keratoplasty indications and outcomes. Cornea. 2010;29(3):296-301.
[59] LOHCHAB M, PRAKASH G, ARORA T, et al. Surgical management of peripheral corneal thinning disorders. Surv Ophthalmol. 2019;64(1): 67-78.
[60] LIANG T, WANG X, WU J, et al. Small-diameter acellular porcine corneal stroma for peripheral corneal ulceration treatment. Int J Ophthalmol. 2024;17(5):831-837.
[61] YOKOYAMA K, NAKAMURA R, OTSUKA T, et al. Deep Anterior Lamellar Keratoplasty and Peripheral Lamellar Keratoplasty for a Case of Severe Peripheral Ulcerative Keratitis. Case Rep Ophthalmol. 2022;13(1):9-16.
[62] ARTAECHEVARRIA ARTIEDA J, ESTéBANEZ-CORRALES N, SÁNCHEZ-PERNAUTE O, et al. Peripheral Ulcerative Keratitis in a Patient with Bilateral Scleritis: Medical and Surgical Management. Case Rep Ophthalmol. 2020;11(3):500-506.
[63] ARUN K, GEORGOUDIS P. Pseudomonas Keratitis: From Diagnosis to Successful Deep Anterior Lamellar Keratoplasty. Cureus. 2024;16(3):e56154.
[64] SHARMA A, SHARMA R. Customized therapeutic deep anterior lamellar keratoplasty in perforated Mooren’s ulcer: A novel technique. Indian J Ophthalmol. 2024;72(1):130-133.
[65] LI J, YU L, DENG Z, et al. Deep anterior lamellar keratoplasty using acellular corneal tissue for prevention of allograft rejection in high-risk corneas. Am J Ophthalmol. 2011;152(5):762-70.e3.
[66] 刘景晨,李明军,孙曙光.眼科领域应用的脱细胞组织材料[J].中国组织工程研究,2021,25(34):5530-5536.
[67] CHEN Y, ZHANG L, LIU Z, et al. Efficacy of Lamellar Keratoplasty with Acellular Porcine Corneal Stroma in Treatment for Infectious Central and Peripheral Corneal Ulcers. Ther Clin Risk Manag. 2021;17:623-634.
[68] WANG Y, XU L, ZHAO J, et al. Reconstructing auto tissue engineering lamellar cornea with aspartic acid modified acellular porcine corneal stroma and preconditioned limbal stem cell for corneal regeneration. Biomaterials. 2022; 289:121745.
|